March 7, 2025 01:25 PM ESTUpdated 02:35 PM
Deals
Cell/Gene Tx

How blue­bird's buy­out of­fer went from $100M up­front to $29M

Kyle LaHucik

Senior Reporter

Blue­bird bio went from a high-fly­ing $10 bil­lion com­pa­ny in 2018 dur­ing the hey­day of gene ther­a­py to be­ing sold for a measly $29 mil­lion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Could Kennedy's FDA cuts trig­ger an ob­scure claw­back pro­vi­sion for in­dus­try user fees?

Phar­ma CEOs warn EU of po­ten­tial ‘ex­o­dus to the US’ as trade war con­tin­ues

NIH ap­peals na­tion­wide block on pay­ment cap for re­search grantees

Amid Trump’s re­search cuts, com­mis­sion says US risks los­ing biotech race with­out $15B in­vest­ment

Ex­clu­sive: Meri­da Bio­sciences gets $121M to treat au­toim­mune and al­ler­gy dis­eases at their roots

No­vo Nordisk, HHS clash over ‘ne­go­ti­a­tion-el­i­gi­ble’ drugs in IRA ap­peals fight

A service from the Financial Times